Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome

Shalini Shenoy, Susan Arnold, Talal Chatila

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

We report a child who developed autoimmune lymphoproliferative syndrome (ALPS) secondary to a heterozygous dominant negative mutation in the death domain of the Fas receptor. Previously developmentally normal, he had symptoms of autism with rapid regression in developmental milestones coincident with the onset of lymphoproliferation and autoimmune hemolytic anemia. Low-dose steroid therapy induced early and complete remission in the ALPS phenotype. There was subjective improvement, followed by objective improvement in speech and developmental milestones. We propose that autism may be part of the autoimmune disease spectrum of ALPS in this child, and this case represents a novel manifestation and target organ involvement in this disease.

Original languageEnglish (US)
Pages (from-to)682-687
Number of pages6
JournalJournal of Pediatrics
Volume136
Issue number5
DOIs
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome'. Together they form a unique fingerprint.

  • Cite this